Notwithstanding positive clinical data, copyright's Vyndamax, a medication for hereditary transthyretin-mediated amyloidosis (hATTR), is facing considerable opposition from pharmacy benefit managers. Such companies are frequently erecting limitations to coverage, such as significant expense crite